drugset
drugset / Trial / NCT06160622

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease

NCT06160622 ↗

Phase 1 Completed 16 enrolled Guangdong Raynovent Biotech Co., Ltd
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will assess the effect of severe kidney impairment on the pharmacokinetics (PK), safety and tolerability of Leritrelvir.

Timeline

Start
2023-09-26
Primary completion
2023-12-12
Completion
2023-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Leritrelvir Unknown 400 mg Oral

Indications

impaired renal function disease